

Code of Federal Regulations

Title 21. Food and Drugs

Chapter I. Food and Drug Administration, Department of Health and Human Services (Refs & Annos)

Subchapter H. Medical Devices

Part 807. Establishment Registration and Device Listing for Manufacturers and Initial Importers of Devices (Refs & Annos)

Subpart E. Premarket Notification Procedures

21 C.F.R. § 807.92

§ 807.92 Content and format of a 510(k) summary.

Currentness

(a) A 510(k) summary shall be in sufficient detail to provide an understanding of the basis for a determination of substantial equivalence. FDA will accept summaries as well as amendments thereto until such time as FDA issues a determination of substantial equivalence. All 510(k) summaries shall contain the following information:

(1) The submitter's name, address, telephone number, a contact person, and the date the summary was prepared;

(2) The name of the device, including the trade or proprietary name if applicable, the common or usual name, and the classification name, if known;

(3) An identification of the legally marketed device to which the submitter claims equivalence. A legally marketed device to which a new device may be compared for a determination regarding substantial equivalence is a device that was legally marketed prior to May 28, 1976, or a device which has been reclassified from class III to class II or I (the predicate), or a device which has been found to be substantially equivalent through the 510(k) premarket notification process;

(4) A description of the device that is the subject of the premarket notification submission, such as might be found in the labeling or promotional material for the device, including an explanation of how the device functions, the scientific concepts that form the basis for the device, and the significant physical and performance characteristics of the device, such as device design, material used, and physical properties;

(5) A statement of the intended use of the device that is the subject of the premarket notification submission, including a general description of the diseases or conditions that the device will diagnose, treat, prevent, cure, or mitigate, including a description, where appropriate, of the patient population for which the device is intended. If the indication statements are different from those of the legally marketed device identified in paragraph (a)(3) of this section, the 510(k) summary shall contain an explanation as to why the differences are not critical to the intended therapeutic, diagnostic, prosthetic, or surgical use of the device, and why the differences do not affect the safety and effectiveness of the device when used as labeled; and

(6) If the device has the same technological characteristics (i.e., design, material, chemical composition, energy source) as the predicate device identified in paragraph (a)(3) of this section, a summary of the technological characteristics of the new device in comparison to those of the predicate device. If the device has different technological characteristics from the

predicate device, a summary of how the technological characteristics of the device compare to a legally marketed device identified in paragraph (a)(3) of this section.

(b) 510(k) summaries for those premarket submissions in which a determination of substantial equivalence is also based on an assessment of performance data shall contain the following information:

(1) A brief discussion of the nonclinical tests submitted, referenced, or relied on in the premarket notification submission for a determination of substantial equivalence;

(2) A brief discussion of the clinical tests submitted, referenced, or relied on in the premarket notification submission for a determination of substantial equivalence. This discussion shall include, where applicable, a description of the subjects upon whom the device was tested, a discussion of the safety or effectiveness data obtained from the testing, with specific reference to adverse effects and complications, and any other information from the clinical testing relevant to a determination of substantial equivalence; and

(3) The conclusions drawn from the nonclinical and clinical tests that demonstrate that the device is as safe, as effective, and performs as well as or better than the legally marketed device identified in paragraph (a)(3) of this section.

(c) The summary should be in a separate section of the submission, beginning on a new page and ending on a page not shared with any other section of the premarket notification submission, and should be clearly identified as a “510(k) summary.”

(d) Any other information reasonably deemed necessary by the agency.

Credits

[[57 FR 18066](#), April 28, 1992; [57 FR 23059](#), June 1, 1992; [59 FR 64295](#), Dec. 14, 1994]

SOURCE: [42 FR 42526](#), Aug. 23, 1977; [51 FR 33032](#), Sept. 18, 1986; [54 FR 39640](#), Sept. 27, 1989; [58 FR 46522](#), Sept. 1, 1993; [62 FR 51519](#), Oct. 1, 1997; [66 FR 5466](#), Jan. 19, 2001; [66 FR 59159](#), Nov. 27, 2001, unless otherwise noted.

AUTHORITY: [21 U.S.C. 321](#), [331](#), [351](#), [352](#), [360](#), [360c](#), [360e](#), [360i](#), [360j](#), [371](#), [374](#), [381](#), [393](#); [42 U.S.C. 264](#), [271](#).

[Notes of Decisions \(38\)](#)

Current through Dec. 3, 2015; [80 FR 75638](#).